Alaunos Therapeutics (TCRT) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	ZIOP
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	1107421
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		128,232,537

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$129,684	$42,803
Receivables	62	145
Prepaid expenses and other current assets	857	1,139
Total current assets	130,603	44,087
Property and equipment, net	426	531
Deposits	128	128
Other non-current assets	491	491
Total assets	131,648	45,237
Current liabilities:
Accounts payable	779	2,004
Accrued expenses	8,220	7,182
Deferred revenue-current portion	1,088	1,360
Deferred rent-current portion	405	280
Total current liabilities	10,492	10,826
Deferred rent	553	570
Total liabilities	11,045	11,396
Commitments and contingencies (note 6)
Stockholders' equity:
Common stock, $0.001 par value; 250,000,000 shares authorized; 128,232,537 and 104,452,105 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	128	104
Additional paid-in capital-common stock	571,318	406,349
Accumulated deficit	-450,843	-372,612
Total stockholders' equity	120,603	33,841
Total liabilities and stockholders' equity	$131,648	$45,237

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	128,232,537	104,452,105
Common stock, shares outstanding	128,232,537	104,452,105

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Research contract revenue	$272	$200
Operating expenses:
Research and development, including costs of research contracts	74,249	6,542
General and administrative	4,250	3,442
Total operating expenses	78,499	9,984
Loss from operations	-78,227	-9,784
Other income (expense), net	-4	-9
Change in fair value of warrants		82
Net loss	($78,231)	($9,711)
Net loss per share-basic and diluted	($0.69)	($0.10)
Weighted average common shares outstanding used to compute net loss per share-basic and diluted	113,410,250	100,229,200

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital Common Stock	Accumulated Deficit
In Thousands, except Share data
Beginning Balance at Dec. 31, 2014	$33,841	$104	$406,349	($372,612)
Beginning Balance (in shares) at Dec. 31, 2014		104,452,105
Stock-based compensation	1,093		1,093
Exercise of employee stock options (in shares)	592,200	592,200
Exercise of employee stock options	2,541		2,541
Repurchase of restricted common stock (in shares)		-33,931
Repurchase of restricted common stock	-246		-246
Issuance of common stock in public offering (in shares)		11,500,000
Issuance of common stock in public offering	94,320	12	94,308
Issuance of common stock in licensing agreement (in shares)		11,722,163
Issuance of common stock in licensing agreement	67,285	12	67,273
Net loss	-78,231			-78,231
Ending Balance at Mar. 31, 2015	$120,603	$128	$571,318	($450,843)
Ending Balance (in shares) at Mar. 31, 2015		128,232,537

STATEMENT_OF_STOCKHOLDERS_EQUI1

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Issuance of common stock in public offering, issuance expenses	$267

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($78,231)	($9,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	122	124
Stock-based compensation	1,093	1,223
Change in fair value of warrants		-82
Common stock issued in exchange for license agreement	67,285
(Increase) decrease in:
Receivables	83	118
Prepaid expenses and other current assets	282	359
Other noncurrent assets		11
Increase (decrease) in:
Accounts payable	-1,224	156
Accrued expenses	1,037	-605
Deferred revenue	-272	-200
Deferred rent	108	-47
Net cash used in operating activities	-9,717	-8,654
Cash flows from investing activities:
Purchases of property and equipment	-17	-2
Net cash used in investing activities	-17	-2
Cash flows from financing activities:
Proceeds from exercise of stock options	2,541	969
Payments to employees for repurchase of common stock	-246	-132
Proceeds from the issuance of common stock, net	94,320
Net cash provided by financing activities	96,615	837
Net increase (decrease) in cash and cash equivalents	86,881	-7,819
Cash and cash equivalents, beginning of period	42,803	68,204
Cash and cash equivalents, end of period	129,684	60,385
Supplementary disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplementary disclosure of noncash investing and financing activities:
Issuance of common stock in license agreement	$67,285

Business

Business	3 Months Ended
	Mar. 31, 2015
Business	1. Business
	Overview
	ZIOPHARM Oncology, Inc., which is referred to as “ZIOPHARM” or the “Company”, is a biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with partners, a diverse portfolio of cancer therapies that can address unmet medical needs.
	The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31.
	The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2015, the Company’s accumulated deficit was approximately $450.8 million. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be obtained by the Company, or if obtained, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations.
	Basis of Presentation
	The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations.
	It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2014, included in the Company’s Form 10-K, for such fiscal year.
	The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States.
	The results disclosed in the Statements of Operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full fiscal year.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
	The Company’s most significant estimates and judgments used in the preparation of its financial statements are:
		•	Clinical trial expenses;
		•	Fair value measurements for stock based compensation; and
		•	Income taxes.
	Subsequent Events
	The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below and the Ares Trading Agreement in footnote 6, the Company did not have any other material subsequent events that impacted its financial statements or disclosures.
	On May 7, 2015, the Company announced the appointment of Laurence J. N. Cooper, M.D., Ph.D., to the position of Chief Executive Officer. Dr. Cooper brings extensive experience in pioneering the development of adoptive cellular therapies in the field of oncology and translating immunology into clinical practice. Jonathan Lewis, M.D., Ph.D., the Company’s former Chief Executive Officer remains a member of its Board of Directors. Prior to becoming the Company’s Chief Executive Officer, Dr. Cooper was a tenured professor at The University of Texas MD Anderson Cancer Center, which he joined in 2006. In addition to being a tenured professor of Pediatrics and Immunology, Dr. Cooper’s other appointments at MD Anderson included Section Chief, Cell Therapy, Children’s Cancer Hospital; and Associate Director, Center for Cancer Immunology Research. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Cooper has received numerous awards and honors and in addition to numerous other professional appointments, he has authored more than 140 journal articles, book chapters, and abstracts. Dr. Cooper has been appointed a Visiting Scientist at MD Anderson where he will continue to direct the efforts of the Cooper Lab.

Financings

Financings	3 Months Ended
	Mar. 31, 2015
Financings	2. Financings
	On February 3, 2015, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 10,000,000 shares of its common stock. The price to the public in the offering was $8.75 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $8.225 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,500,000 shares of common stock at a purchase price of $8.225 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-201826) previously filed with the SEC, and a prospectus supplement thereunder. The underwriters purchased the 10,000,000 shares and the additional 1,500,000 shares on February 9 and February 17, 2015, respectively. The net proceeds from the offering were approximately $94.3 million after deducting underwriting discounts and estimated offering expenses payable by the Company.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies
	The Company’s significant accounting policies were identified in the Company’s Form 10-K for the fiscal year ended December 31, 2014. There have been no material changes in those policies since the filing of its Form 10-K.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Measurements	4. Fair Value Measurements
	The Company accounts for its financial assets and liabilities using fair value measurements. The accounting standard defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 are as follows:
	($ in thousands)				Fair Value Measurements at Reporting Date Using
	Description		Balance as of		Quoted Prices in		Significant Other		Significant
			March 31, 2015		Active Markets for		Observable Inputs		Unobservable Inputs
					Identical		(Level 2)		(Level 3)
					Assets/Liabilities
					(Level 1)
	Cash equivalents		$	119,025	$	119,025	$	—	$	—
	($ in thousands)		Fair Value Measurements at Reporting Date Using
	Description		Balance as of		Quoted Prices in		Significant Other		Significant
			December 31,		Active Markets for		Observable Inputs		Unobservable
			2014		Identical		(Level 2)		Inputs (Level 3)
					Assets/Liabilities
					(Level 1)
	Cash equivalents		$	37,290	$	37,290	$	—	$	—
	The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Net Loss per Share	5. Net Loss per Share
	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at March 31, 2015 and 2014 consist of the following:
		March 31,
		2015		2014
	Stock options		5,924,297		6,159,828
	Unvested restricted common stock		96,073		296,406
	Warrants		—		10,539,767
			6,020,370		16,996,001

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies	6. Commitments and Contingencies
	Operating Leases
	Prior to December 31, 2012, the Company entered into an operating lease in New York, NY, consisting of 6,251 square feet of office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding 1,008 square feet of office space. As of December 31, 2012, the Company occupied 7,259 square feet of space in New York, NY, and maintained a $388 thousand letter of credit. The collateral for the letter of credit is recorded in other non-current assets on the balance sheet as of March 31, 2015. The lease for office space in New York, NY expires in October 2018.
	On October 17, 2013, the Company entered into a sublease agreement to lease 7,259 square feet in its New York office to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. The Company retired assets in this subleased area as a result of this sublease with a net book value of $392 thousand, and recorded a loss on disposal of fixed assets for the same amount for the year ended December 31, 2013. The Company continues to maintain a $388 thousand letter of credit. The collateral for the letter of credit is recorded in other non-current assets on the balance sheet as of March 31, 2015. The lease for office space in New York, NY expires in October 2018.
	Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. That space consisted of 5,249 square feet on the first floor, 8,538 square feet on the second floor, and 6,959 square feet on the third floor. In June 2012, the Company re-negotiated a master lease for the entire Boston office space, added 9,800 square feet of office space on the fourth floor, surrendered 4,113 square feet from the second floor, and incorporated all floors’ lease agreements under the same master agreement expiring in August 2016. The Company provided an additional $41 thousand security deposit for the additional space on the fourth floor. As of March 31, 2015, a total security deposit of $127 thousand is included in deposits on the balance sheet.
	On August 30, 2013, the Company entered into a sublease agreement to lease 5,249 square feet in our Boston office to a subtenant. The Company remains liable to pay rent on the original lease. This sublease tenant vacated the lease in October 2014. As of December 31, 2014, the Company applied the $20 thousand deposit against outstanding rent. As of March 31, 2015, the company concluded that it was unlikely to locate a sublease tenant for a short period lease and recorded an additional loss on this sublease of $167 thousand representing the remaining contractual obligation.
	As of March 31, 2015, the Company occupies 21,184 square feet of space in its Boston, MA office and has paid a total of $127 thousand for security deposits, which are recorded in other non-current assets on the balance sheet.
	Total rent expense was approximately $177 thousand and $167 thousand for the three months ended March 31, 2015 and 2014, respectively.
	The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at March 31, 2015 and 2014 of $958 thousand ($405 thousand current and $553 thousand long-term) and $1.0 million ($224 thousand current and $792 thousand long-term), respectively, which is recorded in deferred rent on the balance sheet.
	License Agreements
	Exclusive Channel Partner Agreement with Intrexon Corporation
	On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement, or the Channel Agreement, with Intrexon that governs a “channel partnering” arrangement in which the Company uses Intrexon’s technology directed towards in vivo expression of effectors in connection with the development of Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex and generally to research, develop and commercialize products, in each case in which DNA is administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which the Company collectively refer to as the Cancer Program. The Channel Agreement establishes committees comprised of representatives of the Company and Intrexon that govern activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.
	The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which is collectively referred to as the ZIOPHARM Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of ZIOPHARM Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense the rights described without Intrexon’s written consent.
	Under the Channel Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the Cancer Program, including development, commercialization and certain aspects of manufacturing of ZIOPHARM Products. Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents.
	Subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company will pay Intrexon on a quarterly basis 50% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by- ZIOPHARM Product basis. The Company has likewise agreed to pay Intrexon on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party’s execution and delivery of the Channel Agreement, the Company entered into a Stock Purchase Agreement with Intrexon.
	Upon termination of the Channel Agreement, the Company may continue to develop and commercialize any ZIOPHARM Product that, at the time of termination:
		•	Is being commercialized by the Company;
		•	Has received regulatory approval;
		•	Is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or
		•	Is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to an uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial in the field (in the case of a termination by the Company due to an uncured breach or a termination by Intrexon following an unconsented assignment by the Company or our election not to pursue development of a Superior Therapy).
	The Company’s obligation to pay 50% of net profits or revenue described above with respect to these “retained” products will survive termination of the Channel Agreement.
	On March 27, 2015, the Company and Intrexon entered into the Exclusive Channel Partner Amendment, or the ECP, amending the Channel Agreement. The ECP Amendment modifies the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T-Cell products to be developed and commercialized pursuant to the Ares Trading Agreement shall be included within the Intrexon/ZIOPHARM collaboration under the Channel Agreement. The ECP Amendment provides that Intrexon will pay to the Company fifty percent of all payments Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement.
	License Agreement—The University of Texas M. D. Anderson Cancer Center
	On January 13, 2015, the Company, together with Intrexon, entered into a License Agreement with MD Anderson. Pursuant to the License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies arising from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson, as well as either co-exclusive or non-exclusive licenses under certain related technologies.
	Pursuant to the terms of the License, MD Anderson received consideration of $50 million in shares of the Company’s common stock (or 10,124,561 shares), and $50 million in shares of Intrexon’s common stock in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the License, collectively referred to as the License Shares, pursuant to the terms of the License Shares Securities Issuance Agreement described below.
	In addition, pursuant to the License, MD Anderson has agreed to transfer to the Company certain existing research programs described in the License and to grant to Intrexon and the Company certain additional technology rights related thereto. In connection with such transfer, the terms of the License also require the Company and Intrexon to enter into a research and development agreement with MD Anderson pursuant to which the Company will provide funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15 and $20 million per year. The first quarterly payment of $3.75 million due under this arrangement was paid on April 13, 2015.
	The term of the License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the License; provided, however, that following the expiration of the term, the Company and Intrexon shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the License and subject to a 90 day cure period, MD Anderson will have the right to convert the License into a non-exclusive license if the Company and Intrexon are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the License and subject to a 180 day cure period, MD Anderson will have the right to terminate the License with respect to specific technology(ies) funded by the government or subject to a third party contract if the Company and Intrexon are not meeting the diligence requirements in such funding agreement or contract, as applicable. Subject to a 30 day cure period, MD Anderson has the right to terminate the License if the Company and Intrexon fail to timely deliver the shares due in consideration for the License. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Intrexon, if such breach has not been cured within 60 days of receiving such notice. In addition, the License will terminate upon the occurrence of certain insolvency events for both the Company and Intrexon and may be terminated by the mutual written agreement of the Company, Intrexon and MD Anderson.
	On January 9, 2015, in order to induce MD Anderson to enter into the License on an accelerated schedule, the Company and Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the Letter Agreement, collectively referred to as the Incentive Shares, in the event that the License was entered into on or prior to 8:00 am pacific time on January 14, 2015, referred to as the Accelerated Closing Deadline. The Incentive Shares were issued to MD Anderson on March 11, 2015 pursuant to the terms of the Incentive Shares Securities Issuance Agreement described below.
	In connection with the entry into the License, on January 13, 2015, the Company entered into a Securities Issuance Agreement with MD Anderson, or the License Shares Securities Issuance Agreement, pursuant to which the Company agreed to issue and sell the License Shares to MD Anderson in consideration for the License. The closing of the issuance and sale of the License Shares under the License Shares Securities Issuance Agreement occurred on March 11, 2015.
	In connection with the entry into the Letter Agreement, on January 13, 2015, the Company entered into a Securities Issuance Agreement with MD Anderson, or the Incentive Shares Securities Issuance Agreement, pursuant to which the Company agreed to issue and sell the Incentive Shares to MD Anderson in consideration for the execution and delivery of the License on or prior to the Accelerated Closing Deadline in connection with the Letter Agreement. The closing of the issuance and sale of the Incentive Shares under the Incentive Shares Securities Issuance Agreement occurred on March 11, 2015.
	Also in connection with the License and the issuance of the License Shares and the Incentive Shares, on January 13, 2015, the Company and MD Anderson entered into a Registration Rights Agreement, or the Registration Rights Agreement, pursuant to which the Company agreed to file a “resale” registration statement, or the Registration Statement, registering the resale of the License Shares, the Incentive Shares and any other shares of the Company’s common stock held by MD Anderson on the date that the Registration Statement is filed, within 15 days of the closing under the License Shares Securities Issuance Agreement. Under the Registration Rights Agreement, the Company is obligated to use its reasonable best efforts to cause the Registration Statement to be declared effective as promptly as practicable after filing and in no event later than 120 days of the closing under the License Shares Securities Issuance Agreement and to maintain the effectiveness of the Registration Statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions. A prospectus supplement under the Company’s already effective registration statement on Form S-3 (SEC File No. 333-201826), was filed on April 1, 2015 in satisfaction of the Company’s obligations under the Registration Rights Agreement.
	The Company has determined that the rights acquired in the License represent in process research and development with no alternative future use. Accordingly, during the three months ended March 31, 2015, the Company recorded a charge of $67.3 million to research and development expense representing the fair value of the 11,722,163 shares of its common stock on the date the license was executed.
	Ares Trading License and Collaboration Agreement
	On March 27, 2015, the Company and Intrexon entered into the Ares Trading Agreement with Ares Trading, a company within the pharmaceutical business of Merck KGaA, Darmstadt, Germany, through which the parties established a collaboration for the research and development and commercialization of Products (as defined below) for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans, which we refer to as the Field.
	The Ares Trading Agreement provides for the establishment of committees composed of Ares Trading and Intrexon representatives that will govern activities in, among others, the areas of project establishment, research plans and intellectual property.
	The Ares Trading Agreement grants Ares Trading an exclusive, worldwide, royalty-bearing, sub-licensable license under the Company’s and Intrexon’s patents, know-how and proprietary platform of research tools and technology necessary for the Company and Intrexon to perform their tasks directed towards the design, identification, culturing, and/or production of genetically modified cells to (a) generate and test Chimeric Antigen Receptor T-Cell Products (as defined in the Ares Trading Agreement) solely for the development, regulatory approval and commercialization of Products containing such Chimeric Antigen Receptor T-Cell Products pursuant to the licenses granted in clauses (b) and (c) of this paragraph; (b) develop and commercialize Products in the Field, worldwide, provided that such Products are not Out-of-Scope Products (as defined below) where Ares Trading has not exercised its Option (as defined below); and (c) commercialize the chimeric antigen receptor for Products.
	Exclusivity
	During the term of the Ares Trading Agreement, subject to the change in control provisions described below, neither the Company nor Intrexon may, directly or indirectly, clinically develop or commercialize any chimeric antigen receptor or Chimeric Antigen Receptor T-Cell Products in the Field other than pursuant to the Ares Trading Agreement, or grant any third party the right to research, develop or commercialize any chimeric antigen receptor or Chimeric Antigen Receptor T-Cell Products in the Field, other than pursuant to the Ares Trading Agreement, or, in the case of Intrexon, pursuant to its rights of independent development as described below. In addition, neither the Company nor Intrexon may, directly or indirectly, clinically develop or commercialize any chimeric antigen receptor or Chimeric Antigen Receptor T-Cell Products in the Field against a Target in animal health.
	If Ares Trading fails to exercise its Option with respect to an Out-of-Scope Target as described below, Ares Trading may not directly or indirectly, clinically develop or commercialize any Chimeric Antigen Receptor T-Cell Product against such Out-of-Scope Target under the Ares Trading Agreement.
	Consideration and Royalties
	Ares Trading will pay an upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Intrexon will pay 50% of the fee to the Company in accordance with the ECP Amendment, discussed above. Ares Trading will, pursuant to the terms of the Ares Trading Agreement, pay Intrexon certain fees for the research and development activities related to the Products.
	Subject to certain expense allocations, Ares Trading will pay Intrexon royalties ranging from the lower-single digits to the lower-double digits of the net sales derived from the sale of Products developed under the Ares Trading Agreement, on a Product-by-Product and a country-by-country basis, which royalties are subject to increase under the Option, as described below. Royalty amounts are subject to adjustment, and the royalty term will terminate, based upon certain conditions as further described in the Ares Trading Agreement. In accordance with the ECP Amendment, Intrexon will pay to the Company 50% of all royalties that it receives under the Ares Trading Agreement.
	The Agreement initially covers two Targets (as defined below) for which Ares Trading must pay a cash fee. Ares Trading may elect additional Targets by paying Intrexon a cash fee.
	Milestones
	Ares Trading has to make certain payments to Intrexon upon Ares Trading’s achievement of designated milestones. Intrexon will pay 50% of all milestones that it receives under the Ares Trading Agreement to the Company under the ECP Amendment. These payments are payable in cash and are generally due within 30 days of the achievement of the relevant milestone.
	Development and commercial milestones. Development milestone payments (not to exceed a capped amount per Product) are payable, on a Product-by-Product basis, upon events further defined in the Ares Trading Agreement with respect to the first four approved indications for the Product. Ares Trading shall also make commercial milestone payments with respect to each Product upon the achievement in a calendar year of tiers of annual worldwide net sales of the Product. In aggregate, the potential payments for development and commercial milestones shall be up to $413 million per Product (or $826 million for the first two Products).
	Technical milestones. Ares Trading must pay to Intrexon further cash fees upon certain technical achievements further specified in the Agreement.
	Responsibilities
	For each Target selected by Ares Trading, Intrexon is responsible for conducting research and development and the manufacture and supply of Products for use in each Phase 1 clinical trial. Ares Trading is responsible for manufacturing and supplying Products for development use after each Phase 1 clinical trial and for commercialization in the Field.
	“Product” means (a) any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by Intrexon under a research program for which the joint steering committee established under the Ares Trading Agreement determines to file an investigational new drug application or under a research program for which Ares Trading has exercised the Option (as defined below) or (b) any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Ares Trading that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described in clause (a).
	“Target” means a unique molecular species or combination thereof (or naturally occurring allelic variant, glycosylation variant, or mutant thereof) that (a) is chemically distinct from other molecules, (b) is a human peptide, protein, polysaccharide or lipid, and (c) wherein a binding entity derives recognized therapeutic value from binding such molecular species.
	Option
	Intrexon may suggest a Target to Ares Trading, and if Ares Trading decides not to include such Target in a research program, it would be deemed to be an “Out-of-Scope Target” under the Ares Trading Agreement, Intrexon may, subject to certain conditions, independently exploit Products directed toward such Out-of-Scope Target at its own cost. The Ares Trading Agreement refers to such products as Out-of-Scope Products. Notwithstanding the foregoing, Intrexon may not develop a cell targeting an Out-of-Scope Target in the Field that according to the term defined in the Agreement would qualify as a “Competitive Product”. At the stage of finalization of the Phase 1 clinical trial enrollment of the first Out-of-Scope Product related to the Out-of-Scope Target, Ares Trading may exercise an option, or the Option, to make the Out-of-Scope Product a Product under the Ares Trading Agreement by notifying Intrexon it is doing so and by paying Intrexon a cash fee and paying increased royalties to Intrexon on such Product covered by the exercise of Ares Trading’s Option, subject to the other terms and conditions relating to royalty payments.
	If Ares Trading does not exercise the Option related to an Out-of-Scope Target and Out-of Scope Product, Intrexon may further exploit such Out-of-Scope Target and Out-of Scope Product independently from Ares Trading (subject to the restrictions on Intrexon contained in the Ares Trading Agreement, including Intrexon’s obligation not to develop a Competitive Product), in consideration for which (i) Intrexon must pay to Ares Trading a lower double digit percentage of all financial and non-financial consideration received by Intrexon for or in connection with such Out-of-Scope Product, up to a capped amount, which is referred to as the One-Time Intrexon Program Option Fee and (ii) once the One-Time Intrexon Program Option Fee has been paid by Intrexon, Intrexon must provide a credit to Ares Trading under the Ares Trading Agreement, subject to certain conditions, of a mid-single digit percentage of all financial and non-financial consideration received by Intrexon for or in connection with such Out-of-Scope Target or Out-of-Scope Product.
	Termination and Change in Control
	Ares Trading may voluntarily terminate, on a Product-by-Product and country-by-country basis or in its entirety, the Ares Trading Agreement upon 90 days’ written notice to Intrexon. Intrexon and Ares Trading may each terminate the Ares Trading Agreement if the other party materially breaches the Ares Trading Agreement and fails to cure the breach.
	Upon termination of the Ares Trading Agreement, Ares Trading, upon written notice to Intrexon, may continue to develop and commercialize any Product (i) for which a Phase 3 clinical trial has been initiated and of which development has not been terminated by Ares Trading or (ii) that is then being commercialized by Ares Trading. The Option and the payment obligations due to Ares Trading each survive termination of the Ares Trading Agreement with respect to research programs initiated by Intrexon for Out-of-Scope Products started before the effective date of termination.
	If either the Company or Intrexon, which for purposes of this paragraph, is referred to as the Acquiring Party, acquires a third party that has a program competitive to that described under the Ares Trading Agreement, the Acquiring Party may either divest such competitive program within 12 months or include all products under the acquired program as Out-of-Scope Products, which would then become subject to the Option.
	If any of the Company, Intrexon, or Ares Trading, which for purposes of this paragraph, is referred to as the Acquired Party, merges with or consolidates with or is acquired by a third party the exclusivity obligations applicable to such person, as described above, will not apply, so long as (i) the competitive program does not use any intellectual property of the Acquired Party or Ares Trading, and (ii) does not utilize services of the personnel of the Acquired Party.
	The Ares Trading Agreement is subject review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 which review is expected to be completed during the second quarter of 2015. Accordingly, the agreement will be accounted for in the second quarter of 2015.
	License Agreement with DEKK-Tec, Inc.
	On October 15, 2004, the Company entered into a license agreement with DEKK-Tec, Inc., pursuant to which it was granted an exclusive, worldwide license for palifosfamide.
	In consideration for the license rights, DEKK-Tec is entitled to receive payments upon achieving certain milestones in varying amounts which on a cumulative basis may total $4.0 million. Of the aggregate milestone payments, most will be creditable against future royalty payments as referenced below. Additionally, the Company issued DEKK-Tec an option to purchase 27,616 shares of the Company’s common stock for $0.02 per share, of which 13,808 options are still outstanding. DEKK-Tec is entitled to receive single digit percentage royalty payments on the sales of palifosfamide should it be approved for commercial sale. The Company’s obligation to pay royalties will terminate on a country-by-country basis upon the expiration of all valid claims of patents in such country covering licensed product, subject to earlier termination in the event of defaults by the parties under the license agreement. No milestones under the license agreement have been reached or expensed since 2010.
	License Agreement with Southern Research Institute
On December 22, 2004, the Company entered into an Option Agreement with the Southern Research Institute, or SRI, pursuant to which the Company was granted an exclusive option to obtain an exclusive license to SRI’s interest in certain intellectual property, including exclusive rights related to certain isophosphoramide mustard analogs. On February 5, 2007, the Company exercised its option and entered into the exclusive license agreement. Under the license agreement, the Company is required to remit minimum annual royalty payments of $25 thousand until the first commercial sale of a licensed product. These payments were made for the years ended December 31, 2014, 2013, and 2012. The Company may be required to make payments upon achievement of certain milestones in varying amounts which on a cumulative basis could total up to $775 thousand. In addition, SRI will be entitled to receive single digit percentage royalty payments on the sales of a licensed product in any country until all licensed patents rights in that country which are utilized in the product have expired. No milestones under the license agreement were reached or expensed since the agreement’s inception.
Patent and Technology License Agreement—The University of Texas M. D. Anderson Cancer Center and the Texas A&M University System.
On August 24, 2004, the Company entered into a patent and technology license agreement with The Board of Regents of the University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.
The Company issued options to purchase 50,222 shares outside the 2003 Stock Option Plan for $0.002 per share following the successful completion of certain clinical milestones, of which 37,666 have vested. The remaining 12,556 shares will vest upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable New Drug Application, or NDA. In addition, the Licensors are entitled to receive certain milestone payments. The Company may be required to make additional payments upon achievement of certain other milestones in varying amounts which on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances.
The license agreement also contains other provisions customary and common in similar agreements within the industry, such as the right to sublicense the Company rights under the agreement. On July 31, 2014, the Company amended and restated the License and Collaboration Agreement between the Company and Solasia Pharma K.K. or Solasia, granting to Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Licensors will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Company’s license agreement with the Licensors.
Collaboration Agreement with Solasia Pharma K.K.
On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K.K., or Solasia.
Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both IV and oral forms and related organic arsenic molecules, in all indications for human use in a pan- Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.
As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. Under the License and Collaboration Agreement, the Company provided Solasia with drug product to conduct clinical trials. These transfers were accounted for as a reduction of research and development costs and an increase in collaboration receivables. The agreement provides that Solasia will be responsible for the development and commercialization of darinaparsin in the pan-Asian/Pacific territory.
On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development-and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Company’s license agreement with the Licensors.
The $5.0 million upfront payment received in March 2011 is being amortized over the period of the Company’s research and development effort. The Company originally estimated this period to be 75 months. In accordance with the amended and restated License and Collaboration Agreement with Solasia, the Company is no longer obligated to continue their research and development efforts in connection with the upfront payment. However, there are certain deliverables that are included in the amended and restated License and Collaboration Agreement including transfer of intellectual property and prior research and development results, which were originally estimated by management to be completed by March 31, 2015 when the amended and restated License and Collaboration Agreement was signed in July 2014 Management subsequently reassessed the period of performance related to the remaining transitional services to be completed under the agreement and determined that the services are now expected to be completed by March 31, 2016. Accordingly, the Company has recorded $272 thousand in revenue during the three months ended March 31, 2015 while the remaining deferred revenue balance of $1.1 million at March 31, 2015 has been classified as current.
License Agreement with Baxter Healthcare Corporation
On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. The terms of the Asset Purchase Agreement included an upfront cash payment and an additional payment for existing inventory. During each of the years ended December 31, 2014, 2013, and 2012, the installment payments of $250 thousand were met and expensed.
Collaboration Agreement with Harmon Hill, LLC
On June 27, 2013, the Company signed a collaboration agreement with Harmon Hill to provide consulting and other services for the development and commercialization of oncology therapeutics by ZIOPHARM, effective April 1, 2013. Under the agreement the Company has agreed to pay Harmon Hill $15 thousand per month for the consulting services. Subject to renewal or extension by the parties, the term of the agreement is for a one year period. The Company expensed $45 thousand and $45 thousand for the three months ended March 31, 2014 and 2015, respectively.
CRO Services Agreement with Novella Clinical, Inc.
On December 4, 2008, the Company entered into a Master Clinical Research Organization Services Agreement with Novella Clinical, Inc., or Novella, under which Novella provides CRO services in support of the Company’s clinical trials. The work order for the newest trial being conducted by Novella was signed on November 2, 2012. Novella was entitled to cumulative payments of up to $790 thousand under these arrangements, which is payable in varying amounts upon Novella achieving specified milestones. During the year ended December 31, 2012, the Company expensed $256 thousand upon the achievement of various milestones. During the year ended December 31, 2013, two database related milestones and one site activation related milestone were met and expensed totaling $136 thousand.
On August 18, 2014 and November 6, 2014, the Company signed two amendments of the Master Clinical Research Organization Services Agreement with Novella. The amendments reflect the removal of data management, statistical and clinical study report services, as well as a change in the timeline and scope of clinical trial support. During the year ended December 31, 2014, three clinical milestones were met and expensed totaling $236 thousand. The remaining milestone of $10 thousand was met and expensed during the quarter ended March 31, 2015.
CRO Services Agreement with MS Clinical Services, LLC.
On July 24, 2014, the Company entered into a Master Clinical Research Organization Services Agreement with MS Clinical Services, LLC, or Medsource, under which Medsource provides CRO services in support of the Company’s clinical trials. There are no milestones associated with this agreement.
CRO Services Agreement with PPD Development, L.P.
The Company was party to a Master Clinical Research Organization Services Agreement with PPD Development, L. P., or PPD, dated January 29, 2010, a related work order dated June 25, 2010 and a related work order dated April 8, 2011 under which PPD provides clinical research organization, or CRO, services in support of the Company’s clinical trials. There are no remaining milestones related to this agreement.
CRO Services Agreement with Pharmaceutical Research Associates, Inc.
On December 13, 2011, the Company entered into a Master Clinical Research Organization Services Agreement with Pharmaceutical Research Associates, Inc., or PRA, under which PRA provides CRO services in support of the Company’s clinical trials. There are no remaining milestones related to this agreement.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions	7. Related Party Transactions
	On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement, or Channel Agreement, with Intrexon Corporation, or Intrexon. The Company’s director, Randall J. Kirk, is the CEO, a director, and the largest stockholder of Intrexon.
	On March 27, 2015, the Company and Intrexon entered into a Second Amendment to Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the worldwide License and Collaboration Agreement, or the Ares Trading Agreement, which the Company and Intrexon entered into with ARES Trading S.A., or Ares Trading, on March 27, 2015. The ECP Amendment provided that Intrexon will pay to the Company fifty percent of all payments that Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement (see Note 6 to the financial statements, Commitments and Contingencies, for additional disclosure relating to the ECP Amendment, the Channel Agreement and the Ares Trading Agreement). The Amendment also reduces Intrexon’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the Existing ECP Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied.
	During the three months ended March 31, 2014, the Company expensed $1.7 million for services performed by Intrexon, of which $0.5 million was recorded in accrued expenses. During the three months ended March 31, 2015, the Company expensed $3.0 million for services performed by Intrexon, of which the full amount is included in accrued expenses at March 31, 2015.
	On February 2, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering (see Note 2 to the financial statements, Financings).
	Intrexon’s common stock purchases were made on terms that were the same as others participating in the above financing.
	On January 13, 2015, the Company, together with Intrexon, entered into a license agreement with The University of Texas M.D. Anderson Cancer Center, or MD Anderson, which is referred to as the License. Pursuant to the License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR-T cell therapies arising from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson, as well as either co-exclusive or non-exclusive licenses under certain related technologies. In partial consideration for entering into the MD Anderson License, the Company also entered into a letter agreement with Intrexon and MD Anderson on January 9, 2015, which is referred to as the MD Anderson Letter Agreement, as well as a Securities Issuance Agreement, which is referred to as the License Shares Securities Issuance Agreement, another Securities Issuance Agreement, which is referred to as the Incentive Shares Securities Issuance Agreement, and a Registration Rights Agreement, which is referred to as the MD Anderson Registration Rights Agreement, with MD Anderson on January 13, 2015. As a result of the common stock issued to MD Anderson in connection with these transactions, MD Anderson became a beneficial holder of more than five percent of the Company’s common stock. (See Note 6 to the financial statements, Commitments and Contingencies, for additional disclosure relating to the License and the transactions contemplated thereby).

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants	8. Warrants
	The Company has issued both warrants that are accounted for as liabilities and warrants that are accounted for as equity instruments.
	The Company follows accounting standards that provide guidance in assessing whether an equity-issued financial instrument is indexed to an entity’s own stock for purposes of determining whether a financial instrument should be treated as a derivative and classified as a liability. Accounting standards require that liability classified warrants be recorded at their fair value at each financial reporting period and the resulting gain or loss be recorded as other income (expense) in the Statements of Operations. Fair value is measured using the binomial valuation model.
	There were no warrants outstanding at March 31, 2015 or December 31, 2014.
	Liability-Classified Warrants
	In connection with the December 2009 public offering, the Company issued warrants to purchase an aggregate of 8,206,520 shares of common stock (including the investor warrants and 464,520 warrants issued to the Underwriters). The investor warrants were exercisable immediately and the underwriter warrants exercisable six months after the date of issuance. The warrants had a 5 year term. Subject to certain exceptions, these warrants provided anti-dilution protection should common stock or common stock equivalents be subsequently issued at a price less than the exercise price of the warrants then in effect.
	The Company assessed whether the 2009 Warrants require accounting as derivatives. The Company determined that these warrants were not indexed to the Company’s own stock in accordance with accounting standards codification Topic 815, Derivatives and Hedging. As such, the Company has concluded these warrants did not meet the scope exception for determining whether the instruments require accounting as derivatives and were classified as liabilities.
	The Company used the Binomial/Monte Carlo pricing model to estimate the value of the liability-classified warrants. The following assumptions were used in the Binomial/Monte Carlo valuation model at March 31, 2014 (no warrants were outstanding during the three months ended March 31, 2015):
		2014
	Risk-free interest rate		0.11	%
	Expected life in years		0.69
	Expected volatility		80	%
	Expected dividend yield		0
	Steps per year		13
	The change in the fair value of the warrant liability resulted in a gain of $82 thousand for the three months ended March 31, 2014. The change in the fair value of the warrant liability was charged to other income (expense) in the Statements of Operations.
	There were no warrant exercises during the three months ended March 31, 2014 and no warrants were outstanding during the three months ended March 31, 2015.

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2015
Common Stock	9. Common Stock
	On February 3, 2015, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 10,000,000 shares of the Company’s common stock. The price to the public in the offering was $8.75 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $8.225 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,500,000 shares of common stock at a purchase price of $8.225 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-201826) previously filed with the SEC, and a prospectus supplement thereunder. The underwriters purchased the 10,000,000 shares and the additional 1,500,000 shares on February 9 and 17, 2015, respectively. The net proceeds from the offering were approximately $94.3 million after deducting underwriting discounts and estimated offering expenses payable by the Company.
	On January 13, 2015, the Company, together with Intrexon, entered into the License with MD Anderson. Pursuant to the License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies arising from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson, as well as either co-exclusive or non-exclusive licenses under certain related technologies.
	Pursuant to the terms of the License, MD Anderson received consideration of $50 million in shares of the Company’s common stock (or 10,124,561 shares), and $50 million in shares of Intrexon’s common stock in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the License, collectively referred to as the License Shares, pursuant to the terms of the License Shares Securities Issuance Agreement. The License Shares were issued on March 11, 2015.
	On January 9, 2015, in order to induce MD Anderson to enter into the License on an accelerated schedule, the Company and Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of the Company’s common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the Letter Agreement, collectively referred to as the Incentive Shares, in the event that the License was entered into on or prior to 8:00 am pacific time on January 14, 2015, referred to as the Accelerated Closing Deadline. The Incentive Shares were issued on March 11, 2015.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Stock-Based Compensation	10. Stock-Based Compensation
	The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:
		For the three months
		ended March 31,
	(in thousands)	2015			2014
	Research and development	$	295		$	376
	General and administrative		798			847
	Stock-based employee compensation expense	$	1,093		$	1,223
	The Company granted 50,000 and 80,500 stock options during the three months ended March 31, 2015 and 2014 that had a weighted-average grant date fair value of $6.58 and $3.34 per share, respectively.
	At March 31, 2015, total unrecognized compensation costs related to unvested stock options outstanding amounted to $7.7 million. The cost is expected to be recognized over a weighted-average period of 1.63 years.
	On March 31, 2014, the Company extended the contractual life of 71,167 fully vested stock options held by one employee by an additional 9 months.
	On March 31, 2014, the Company extended the contractual life of 33,333 fully vested stock options and 66,667 unvested stock options held by one employee.
	On September 8, 2014, the Company extended the contractual life of 82,834 fully vested stock options and 23,333 unvested stock options held by one employee by an additional 3 months.
	On September 15, 2014, the Company extended the contractual life of 39,167 fully vested stock options and 113,333 unvested stock options held by one employee.
	For the three months ended March 31, 2015 and 2014, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:
		For the three months ended March 31,
		2015		2014
	Risk-free interest rate	1.63 - 1.64%		1.76 - 2.11%
	Expected life in years	6		6
	Expected volatility	85.48 - 86.81%		94.46 - 94.55%
	Expected dividend yield	0		0
	Stock option activity under the Company’s stock option plan for the three months ended March 31, 2015 is as follows:
	(in thousands, except share and per share data)	Number of			Weighted-		Weighted-		Aggregate
		Shares			Average Exercise		Average		Intrinsic Value
					Price		Contractual
							Term (Years)
	Outstanding, December 31, 2014		6,505,663		$	4.07
	Granted		50,000			9.1
	Exercised		(592,200	)		4.29
	Cancelled		(39,166	)		4.26
	Outstanding, March 31, 2015		5,924,297		$	4.09		6.36	$	39,564
	Vested and unvested expected to vest at March 31, 2015		5,878,611		$	4.08		5.33	$	39,259
	Options exercisable, March 31, 2015		3,185,297		$	4.08		5.33	$	21,297
	Options exercisable, December 31, 2014		3,781,162		$	4.1		5.8	$	4,130
	Options available for future grant		4,572,935
	A summary of the status of unvested restricted stock for the three months ended March 31, 2015 is as follows:
		Number of Shares			Weighted-Average
					Grant Date Fair Value
	Non-vested, December 31, 2014		144,508		$	4.7
	Granted		—			—
	Vested		(48,435	)		4.51
	Cancelled		—			—
	Non-vested, March 31, 2015		96,073		$	4.79
	At March 31, 2015, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $0.5 million. The cost is expected to be recognized over a weighted-average period of 1.00 years.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 are as follows:
	($ in thousands)			Fair Value Measurements at Reporting Date Using
	Description	Balance as of		Quoted Prices in		Significant Other		Significant
		March 31, 2015		Active Markets for		Observable Inputs		Unobservable Inputs
				Identical		(Level 2)		(Level 3)
				Assets/Liabilities
				(Level 1)
	Cash equivalents	$	119,025	$	119,025	$	—	$	—
	($ in thousands)	Fair Value Measurements at Reporting Date Using
	Description	Balance as of		Quoted Prices in		Significant Other		Significant
		December 31,		Active Markets for		Observable Inputs		Unobservable
		2014		Identical		(Level 2)		Inputs (Level 3)
				Assets/Liabilities
				(Level 1)
	Cash equivalents	$	37,290	$	37,290	$	—	$	—

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at March 31, 2015 and 2014 consist of the following:
		March 31,
		2015		2014
	Stock options		5,924,297		6,159,828
	Unvested restricted common stock		96,073		296,406
	Warrants		—		10,539,767
			6,020,370		16,996,001

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Assumptions Used in Binomial and Monte Carlo Valuation Model	The following assumptions were used in the Binomial/Monte Carlo valuation model at March 31, 2014 (no warrants were outstanding during the three months ended March 31, 2015):
		2014
	Risk-free interest rate		0.11	%
	Expected life in years		0.69
	Expected volatility		80	%
	Expected dividend yield		0
	Steps per year		13

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stock-Based Compensation Expense on All Employee and Non-Employee Awards	The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:
		For the three months
		ended March 31,
	(in thousands)	2015			2014
	Research and development	$	295		$	376
	General and administrative		798			847
	Stock-based employee compensation expense	$	1,093		$	1,223
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model	For the three months ended March 31, 2015 and 2014, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:
		For the three months ended March 31,
		2015		2014
	Risk-free interest rate	1.63 - 1.64%		1.76 - 2.11%
	Expected life in years	6		6
	Expected volatility	85.48 - 86.81%		94.46 - 94.55%
	Expected dividend yield	0		0
Stock Option Activity Under Stock Option Plan	Stock option activity under the Company’s stock option plan for the three months ended March 31, 2015 is as follows:
	(in thousands, except share and per share data)	Number of			Weighted-		Weighted-		Aggregate
		Shares			Average Exercise		Average		Intrinsic Value
					Price		Contractual
							Term (Years)
	Outstanding, December 31, 2014		6,505,663		$	4.07
	Granted		50,000			9.1
	Exercised		(592,200	)		4.29
	Cancelled		(39,166	)		4.26
	Outstanding, March 31, 2015		5,924,297		$	4.09		6.36	$	39,564
	Vested and unvested expected to vest at March 31, 2015		5,878,611		$	4.08		5.33	$	39,259
	Options exercisable, March 31, 2015		3,185,297		$	4.08		5.33	$	21,297
	Options exercisable, December 31, 2014		3,781,162		$	4.1		5.8	$	4,130
	Options available for future grant		4,572,935
Summary of Unvested Restricted Stock	A summary of the status of unvested restricted stock for the three months ended March 31, 2015 is as follows:
		Number of Shares			Weighted-Average
					Grant Date Fair Value
	Non-vested, December 31, 2014		144,508		$	4.7
	Granted		—			—
	Vested		(48,435	)		4.51
	Cancelled		—			—
	Non-vested, March 31, 2015		96,073		$	4.79

Business_Additional_Informatio

Business - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Nature Of Operations [Line Items]
Accumulated deficit	($450,843)	($372,612)

Financings_Additional_Informat

Financings - Additional Information (Detail) (J.P. Morgan Securities Inc., USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 17, 2015	Feb. 03, 2015	Feb. 03, 2015
J.P. Morgan Securities Inc.
Class of Stock [Line Items]
Stock issued during period	1,500,000	10,000,000
Issuance & sale of common stock in public offering price per share		$8.75	$8.75
Option granted, exercisable period		30 days
Option to purchase common stock	1,500,000	1,500,000
Sale of stock price per share		$8.22	$8.22
Expected net proceeds from issuance of common stock	$94.30

Assets_and_Liabilities_Measure

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$119,025	$37,290
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$119,025	$37,290

Potential_Dilutive_Shares_Excl

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,020,370	16,996,001
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,924,297	6,159,828
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	96,073	296,406
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		10,539,767

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Jan. 13, 2015

Mar. 31, 2015

Mar. 31, 2014

Apr. 13, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Aug. 24, 2004

Mar. 07, 2011

Jun. 27, 2013

Jan. 06, 2011

Jan. 09, 2015

Oct. 17, 2013

Aug. 30, 2013

Dec. 31, 2011

Oct. 15, 2014

Jun. 30, 2014

Nov. 02, 2012

Jan. 31, 2012

Jun. 30, 2012

Patent

sqft

sqft

sqft

sqft

Commitments and Contingencies Disclosure [Line Items]

Total rent Expense

$177,000

$167,000

Deferred rent - current portion

405,000

224,000

280,000

Deferred rent-non-current portion

553,000

792,000

570,000

Deferred rent liability net

958,000

1,000,000

Research and development arrangement Terms

In connection with such transfer, the terms of the License also require the Company and Intrexon to enter into a research and development agreement with MD Anderson pursuant to which the Company will provide funding for certain research and development activities of MD Anderson for a period of three years

Research and Development Expense

74,249,000

6,542,000

Research contract revenue

272,000

200,000

Deferred revenue - current portion

1,088,000

1,360,000

Estimated upfront payment for research and development funding earning period

75 months

Subsequent Event

Commitments and Contingencies Disclosure [Line Items]

Research and Development Service Agreement Quarterly Payment

3,750,000

DEKK Tec Inc

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

4,000,000

Option to purchase common stock

27,616

Sale of stock price per share

$0.02

Outstanding options to purchase common stock

13,808

Southern Research Institute

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

775,000

Royalty payment

25,000

25,000

25,000

The University of Texas M.D. Anderson Cancer Center and The Texas A & M University System

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

4,500,000

Option to purchase common stock

50,222

Sale of stock price per share

$0.00

Number of products

2

The University of Texas M.D. Anderson Cancer Center and The Texas A & M University System | Upon enrollment of the first patient in a multi-center pivotal clinical trial

Commitments and Contingencies Disclosure [Line Items]

Shares expected to vest

12,556

Novella Clinical, Inc.

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

790,000

Number of amendments signed

2

Novella Clinical, Inc. | Upon the achievement of various milestones

Commitments and Contingencies Disclosure [Line Items]

Installment payments

256,000

Novella Clinical, Inc. | Upon two database related milestones

Commitments and Contingencies Disclosure [Line Items]

Installment payments

136,000

Novella Clinical, Inc. | Upon three clinical milestones

Commitments and Contingencies Disclosure [Line Items]

Installment payments

10,000

236,000

Baxter Healthcare Corporation | Upon the successful U.S. IND application for indibulin

Commitments and Contingencies Disclosure [Line Items]

Installment payments

250,000

250,000

250,000

Solasia

Commitments and Contingencies Disclosure [Line Items]

Upfront payment received

5,000,000

Solasia | Development-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected Additional milestone payments to be received

32,500,000

Solasia | Sales-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected Additional milestone payments to be received

53,500,000

Harmon Hill LLC | Collaboration Agreement

Commitments and Contingencies Disclosure [Line Items]

Payment for consulting services fee

45,000

45,000

Monthly Payment | Harmon Hill LLC | Collaboration Agreement

Commitments and Contingencies Disclosure [Line Items]

Payment for consulting services fee

15,000

Per Product

Commitments and Contingencies Disclosure [Line Items]

Payments for development and commercial milestones per Product

413,000,000

First Two Products

Commitments and Contingencies Disclosure [Line Items]

Payments for development and commercial milestones per Product

826,000,000

Minimum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

15,000,000

Maximum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

20,000,000

License Agreement

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

67,285,000

Issuance of common stock in licensing agreement, shares

11,722,163

Intrexon Corporation

Commitments and Contingencies Disclosure [Line Items]

Contract termination description

The Companybs obligation to pay 50% of net profits or revenue described above with respect to these bretainedb products will survive termination of the Channel Agreement.

Percentage of up licensing fee paid

50.00%

Percentage of royalty paid

50.00%

Milestone payments, percentage

50.00%

Intrexon Corporation | Quarterly Payment

Commitments and Contingencies Disclosure [Line Items]

Percent of company net profit

50.00%

Percentage of revenue agreed to pay which is obtained from sublicensor

50.00%

Intrexon Corporation | Letter Agreement

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

7,500,000

Intrexon Corporation | License Agreement

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

50,000,000

Ziopharm | Letter Agreement

Commitments and Contingencies Disclosure [Line Items]

Common stock issued for cash

1,597,602

Cash consideration for license agreement

7,500,000

Ziopharm | License Agreement

Commitments and Contingencies Disclosure [Line Items]

Common stock issued for cash

10,124,561

Cash consideration for license agreement

50,000,000

ARES Trading S.A.

Commitments and Contingencies Disclosure [Line Items]

Licensing fee

115,000,000

New York, NY

Commitments and Contingencies Disclosure [Line Items]

Office space under operating lease

7,259

6,251

Letter of credit

388,000

388,000

388,000

Additional office space under operating lease

1,008

Operating lease expiration month and year

2018-10

2018-10

Area under sublease agreement

7,259

Loss on sublease

729,000

Remaining contractual obligation

2,300,000

Sublease revenue from subtenant

1,600,000

Loss on disposal of fixed assets

-392,000

Boston, MA

Commitments and Contingencies Disclosure [Line Items]

Office space under operating lease

21,184

Operating lease expiration month and year

2016-08

Area under sublease agreement

5,249

Loss on sublease

167,000

Security deposits

127,000

Security deposit from subtenant

20,000

Boston, MA | The first floor

Commitments and Contingencies Disclosure [Line Items]

Operating lease space

5,249

Boston, MA | The second floor

Commitments and Contingencies Disclosure [Line Items]

Office space under operating lease

4,113

Operating lease space

8,538

Boston, MA | The third floor

Commitments and Contingencies Disclosure [Line Items]

Operating lease space

6,959

Boston, MA | The four floor

Commitments and Contingencies Disclosure [Line Items]

Office space under operating lease

9,800

Security deposits

41,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 02, 2015	Mar. 27, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Commitment to purchase common stock	$246,000	$132,000
Accrued expenses	8,220,000				7,182,000
Md Anderson Cancer Center | Minimum
Related Party Transaction [Line Items]
Ownership percentage	5.00%
Intrexon Corporation
Related Party Transaction [Line Items]
Amounts paid for services incurred	3,000,000	1,700,000
Accrued expenses	3,000,000	500,000
Stock issued during period			1,440,000
Intrexon Corporation | Before Amendment
Related Party Transaction [Line Items]
Commitment to purchase common stock				50,000,000
Intrexon Corporation | After Amendment
Related Party Transaction [Line Items]
Commitment to purchase common stock				$43,500,000
Percentage of commitment for payments from receipts of upfronts, milestones and royalties				50.00%

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2009	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Warrants to purchase an aggregate of shares of common stock		8,206,520
Warrant term		5 years
Change in fair value of warrants	$82
Warrants exercised	0
Warrants outstanding			0
J. P. Morgan Securities LLC
Class of Warrant or Right [Line Items]
Warrants issued		464,520
Warrant exercisable Period		6 months

Assumptions_Used_In_Binomial_V

Assumptions Used In Binomial Valuation Model and Black-Scholes Valuation Model (Detail) (Black Scholes Option Pricing Model, Warrants)	3 Months Ended
	Mar. 31, 2014
Black Scholes Option Pricing Model | Warrants
Class of Warrant or Right [Line Items]
Risk-free interest rate	0.11%
Expected life in years	8 months 9 days
Expected volatility	80.00%
Expected dividend yield	0.00%
Steps per year	13

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 02, 2015	Jan. 13, 2015	Jan. 09, 2015	Feb. 17, 2015	Feb. 03, 2015
Intrexon Corporation
Class of Stock [Line Items]
Stock issued during period	1,440,000
License Agreement | Ziopharm
Class of Stock [Line Items]
Common stock issued for cash		10,124,561
Cash consideration for license agreement		$50
License Agreement | Intrexon Corporation
Class of Stock [Line Items]
Cash consideration for license agreement		50
Letter Agreement | Ziopharm
Class of Stock [Line Items]
Common stock issued for cash			1,597,602
Cash consideration for license agreement			7.5
Letter Agreement | Intrexon Corporation
Class of Stock [Line Items]
Cash consideration for license agreement			7.5
J.P. Morgan Securities Inc.
Class of Stock [Line Items]
Stock issued during period				1,500,000	10,000,000
Issuance & sale of common stock in public offering price per share					$8.75
Option granted, exercisable period					30 days
Option to purchase common stock				1,500,000	1,500,000
Sale of stock price per share					$8.22
Net proceeds from issuance of common stock				$94.30

StockBased_Compensation_Expens

Stock-Based Compensation Expense Included in Statement of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$1,093	$1,223
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	295	376
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$798	$847

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2015	Sep. 15, 2014	Sep. 08, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	50,000	80,500
Weighted-average grant date fair value	$6.58	$3.34
Unrecognized compensation costs, employee stock options	$7.70			7.7
Employee Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vested			33,333
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period	1 year 7 months 17 days
Vested options held by 1 employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vested				71,167	39,167	82,834
Shares vesting period				9 months
Unvested options held by 1 employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares vesting period						3 months
Shares unvested		66,667	66,667		113,333	23,333
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period	1 year
Unrecognized compensation costs	$0.50			0.5

Fair_Value_of_Stock_Options_As

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.63%	1.76%
Risk-free interest rate, Maximum	1.64%	2.11%
Expected life in years	6 years	6 years
Expected volatility, Minimum	85.48%	94.46%
Expected volatility, Maximum	86.81%	94.55%
Expected dividend yield	0.00%	0.00%

Stock_Option_Activity_Under_St

Stock Option Activity Under Stock Option Plan (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Number of Shares
Beginning Balance	6,505,663
Granted	50,000	80,500
Exercised	-592,200
Cancelled	-39,166
Ending Balance	5,924,297		6,505,663
Vested and unvested expected to vest at end of period	5,878,611
Options exercisable, at end of period	3,185,297		3,781,162
Options available for future grant	4,572,935
Weighted Average Exercise Price
Beginning Balance	$4.07
Granted	$9.10
Exercised	$4.29
Cancelled	$4.26
Ending Balance	$4.09		$4.07
Vested and unvested expected to vest at end of period	$4.08
Options exercisable, at end of period	$4.08		$4.10
Weighted Average Contractual Term (Years)
Outstanding, at end of period	6 years 4 months 10 days
Vested and unvested expected to vest at end of period	5 years 3 months 29 days
Options exercisable, at end of period	5 years 3 months 29 days		5 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding, at end of period	$39,564
Vested and unvested expected to vest at end of period	39,259
Options exercisable, at end of period	$21,297		$4,130

Summary_of_Unvested_Restricted

Summary of Unvested Restricted Stock (Detail) (Unvested Restricted Common Stock, USD $)	3 Months Ended
	Mar. 31, 2015
Unvested Restricted Common Stock
Number of Shares
Beginning Balance	144,508
Granted	0
Vested	-48,435
Cancelled	0
Ending Balance	96,073
Weighted Average Grant Date Fair Value
Beginning Balance	$4.70
Granted	$0
Vested	$4.51
Cancelled	$0
Ending Balance	$4.79